Randomized trial compares NET levels in hypertensive patients across risk groups, indicating potential biomarkers for cardiovascular danger.
Key Points
This research aims to compare plasma levels of neutrophil extracellular traps (NETs) in newly diagnosed hypertensive patients across different cardiovascular risk categories.
Newly diagnosed untreated hypertensive patients were recruited.
Plasma levels of NETs were measured using ELISA, and cardiovascular risk was calculated via ASCVD risk calculator.
Blood pressure parameters were measured according to European guidelines using the Mobil-O-Graph device.
NETs levels differed significantly across ASCVD risk groups (p=0.013).
Intermediate risk group had higher MPO-DNA levels compared to low and borderline groups (post hoc p=0.034 and p=0.001, respectively).